US Bancorp’s Amylyx Pharmaceuticals AMLX Stock Holding History

US Bancorp’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65.4K	Buy	3,639 +1,576	+76%	+$24.4K	﹤0.01%	2673
2026 Q1	$28.7K	Buy	2,063 +63	+3%	+$886	﹤0.01%	2945
2025 Q4	$24.2K	Sell	2,000 -2,000	-50%	-$27.2K	﹤0.01%	3006
2025 Q3	$54.4K	Hold	4,000	–	–	﹤0.01%	2636
2025 Q2	$25.6K	Hold	4,000	–	–	﹤0.01%	3078
2025 Q1	$14.2K	Hold	4,000	–	–	﹤0.01%	3321
2024 Q4	$15.1K	Buy	+4,000	New	+$18.8K	﹤0.01%	3272
2023 Q2	–	Sell	-18	Closed	-$528	–	3989
2023 Q1	$528	Sell	18 -6,977	-100%	-$242K	﹤0.01%	3940
2022 Q4	$258K	Buy	+6,995	New	+$248K	﹤0.01%	1722

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

US Bancorp's AMLX Position: Q2 2026 in Review

US Bancorp increased its Amylyx Pharmaceuticals (AMLX) stake by 76% in Q2 2026, buying an estimated $24.4K and bringing the position to 3,639 shares worth $65.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2673.

US Bancorp first reported a position in AMLX in Q4 2022 and has held it in 9 quarters since. The position peaked at $258K in Q4 2022. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

US Bancorp held 3,639 shares of Amylyx Pharmaceuticals worth $65.4K as of Q2 2026.
US Bancorp bought 1,576 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $24.4K.
Amylyx Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2673 holding.
US Bancorp first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 9 quarters since.
US Bancorp's Amylyx Pharmaceuticals position peaked at $258K in Q4 2022.
206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.